653
edits
Difference between revisions of "Invasive breast cancer"
Jump to navigation
Jump to search
→Molecular classification of invasive carcinoma
| Line 163: | Line 163: | ||
**Most triple negative (ER, PgR, Her-2); therefore cannot be treated with the usual therapeutic agents | **Most triple negative (ER, PgR, Her-2); therefore cannot be treated with the usual therapeutic agents | ||
**There is an association in young women between basal-like breast cancer and BRCA1 mutation. | **There is an association in young women between basal-like breast cancer and BRCA1 mutation. | ||
**Discussions of BRCA1 associated tumors, TNBC and BLBC are typically muddied by the overlap. | |||
**Increased incidence in some populations - African-Americans, young women | **Increased incidence in some populations - African-Americans, young women | ||
**Sporadic basal-like cancers do not have a BRCA1 mutation but may have a dysfunctional BRCA1 pathway. | **Sporadic basal-like cancers do not have a BRCA1 mutation but may have a dysfunctional BRCA1 pathway. | ||
| Line 206: | Line 207: | ||
**Triple-negative and basal-like phenotypes are not synonymous but overlap | **Triple-negative and basal-like phenotypes are not synonymous but overlap | ||
***About 70% of triple-negative tumours are basal-like. | ***About 70% of triple-negative tumours are basal-like. | ||
***About 70% of basal-like tumors are triple-negative tumours are. | ***About 70% of basal-like tumors are triple-negative tumours. | ||
**Discussions of BRCA1 associated tumors, TNBC and BLBC are typically muddied by the overlap. | |||
**Classic 'morphological clues' to a triple negative cancer usually refer to medullary carcinoma features. | **Classic 'morphological clues' to a triple negative cancer usually refer to medullary carcinoma features. | ||
**BCL11A overexpression recently identified as an oncogenic driver in this group <ref>{{Cite journal | last1 = Khaled | first1 = WT. | last2 = Choon Lee | first2 = S. | last3 = Stingl | first3 = J. | last4 = Chen | first4 = X. | last5 = Raza Ali | first5 = H. | last6 = Rueda | first6 = OM. | last7 = Hadi | first7 = F. | last8 = Wang | first8 = J. | last9 = Yu | first9 = Y. | title = BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells. | journal = Nat Commun | volume = 6 | issue = | pages = 5987 | month = | year = 2015 | doi = 10.1038/ncomms6987 | PMID = 25574598 }}</ref> | **BCL11A overexpression recently identified as an oncogenic driver in this group <ref>{{Cite journal | last1 = Khaled | first1 = WT. | last2 = Choon Lee | first2 = S. | last3 = Stingl | first3 = J. | last4 = Chen | first4 = X. | last5 = Raza Ali | first5 = H. | last6 = Rueda | first6 = OM. | last7 = Hadi | first7 = F. | last8 = Wang | first8 = J. | last9 = Yu | first9 = Y. | title = BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells. | journal = Nat Commun | volume = 6 | issue = | pages = 5987 | month = | year = 2015 | doi = 10.1038/ncomms6987 | PMID = 25574598 }}</ref> | ||